Active	Status	Sponsor type	Region	Phase	Filter
6 Active 1 Inactive 7 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

6 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Wang, Peiguo
XRAY VISION, NCT05386550 / 2022-001144-18: Phase III Xevinapant (Debio 1143) and Radiotherapy in Resected LA SCCHN, High Risk, Cisplatin-ineligible Participants	Terminated	3	166	Europe, Canada, Japan, US, RoW	Xevinapant (Debio 1143), IMRT, Placebo	EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany	Head and Neck Cancer	08/24	08/24
NCT04782765: Phase Ⅱ Trial of Camrelizumab in Patients Without Distant Metastasis Nasopharyngeal Carcinoma	Recruiting	2	59	RoW	Camrelizumab+Chemotherapy+Chemoradiotherapy	Tianjin Medical University Cancer Institute and Hospital	Disease-free Survival Rate	03/23	03/25
NCT05372120: A Clinical Trial of ICP-192 in Treated Patients With Advanced Solid Tumors With FGF/FGFR Gene Alterations	Recruiting	2	200	RoW	ICP-192	Beijing InnoCare Pharma Tech Co., Ltd.	Advanced Solid Tumor	12/23	06/24
NCT06214143: A Clinical Study of T3011 in Combination With PD-1/PD-L1 Inhibitors in Subjects With Advanced Solid Tumors	Recruiting	1/2	68	RoW	T3011 high dose, T3011 middle dose, T3011 low dose	Shanghai Pharmaceuticals Holding Co., Ltd	Advanced Solid Tumors	12/25	05/26
Redbull-1, NCT04949503: A Real-world Study of the Efficacy and Safety of Nimotuzumab in Combination With Chemoradiotherapy for LASCCHN	Completed	N/A	1931	RoW	nimotuzumab, chemoradiotherapy	Biotech Pharmaceutical Co., Ltd.	Locally Advanced Head and Neck Squamous Cell Carcinoma	03/23	04/23
Pathak, Anand
XRAY VISION, NCT05386550 / 2022-001144-18: Phase III Xevinapant (Debio 1143) and Radiotherapy in Resected LA SCCHN, High Risk, Cisplatin-ineligible Participants	Terminated	3	166	Europe, Canada, Japan, US, RoW	Xevinapant (Debio 1143), IMRT, Placebo	EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany	Head and Neck Cancer	08/24	08/24